Successful resumption of tocilizumab for rheumatoid arthritis after resection of a pulmonary Mycobacterium avium complex lesion: A case report

Ho Namkoong, Sadatomo Tasaka, Mitsuhiro Akiyama, Kazuma Yagi, Makoto Ishii, Katsuya Suzuki, Mitsutomo Kohno, Naoki Hasegawa, Tsutomu Takeuchi, Tomoko Betsuyaku

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Biological agents inhibiting TNF-aα and other molecules involved in inflammatory cascade have been increasingly used to treat rheumatoid arthritis (RA). However, it remains controversial whether biological agents can be used safely in a patient with an underlying chronic infectious disease. Case presentation: A 63-year-old woman who had been treated with tocilizumab (TCZ), anti-interleukin-6 receptor antibody, for RA presented to our outpatient clinic due to hemoptysis. She was diagnosed with pulmonary Mycobacterium avium complex (MAC) infection, and high-resolution computed tomography (HRCT) showed a single cavitary lesion in the right upper lobe. After diagnosis of pulmonary MAC disease, TCZ was discontinued and combination chemotherapy with clarithromycin, rifampicin, ethambutol and amikacin was started for MAC pulmonary disease. Since the lesion was limited in the right upper lobe as a single cavity formation, she underwent right upper lobectomy. As her RA symptoms were deteriorated around the operation, TCZ was resumed. After resumption of TCZ, her RA symptoms improved and a recurrence of pulmonary MAC infection has not been observed for more than 1 year. Conclusion: This case suggested that TCZ could be safely reintroduced after the resection of a pulmonary MAC lesion. Although the use of biological agents is generally contraindicated in patients with pulmonary MAC disease, especially in those with a fibrocavitary lesion, a multimodality intervention for MAC including both medical and surgical approaches may enable introduction or resumption of biological agents.

Original languageEnglish
Article number126
JournalBMC Pulmonary Medicine
Volume15
Issue number1
DOIs
Publication statusPublished - 2015 Oct 23

Fingerprint

Mycobacterium avium Complex
Rheumatoid Arthritis
Lung
Biological Factors
Interleukin-6 Receptors
Ethambutol
Clarithromycin
Amikacin
Hemoptysis
Rifampin
Ambulatory Care Facilities
Infection
tocilizumab
Combination Drug Therapy
Lung Diseases
Communicable Diseases
Chronic Disease
Tomography
Recurrence
Antibodies

Keywords

  • Biological agents
  • Mycobacterium avium complex (MAC)
  • Resection
  • Rheumatoid arthritis
  • Tocilizumab

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Successful resumption of tocilizumab for rheumatoid arthritis after resection of a pulmonary Mycobacterium avium complex lesion : A case report. / Namkoong, Ho; Tasaka, Sadatomo; Akiyama, Mitsuhiro; Yagi, Kazuma; Ishii, Makoto; Suzuki, Katsuya; Kohno, Mitsutomo; Hasegawa, Naoki; Takeuchi, Tsutomu; Betsuyaku, Tomoko.

In: BMC Pulmonary Medicine, Vol. 15, No. 1, 126, 23.10.2015.

Research output: Contribution to journalArticle

@article{5f16abf729254cd4bdd26a714b14285d,
title = "Successful resumption of tocilizumab for rheumatoid arthritis after resection of a pulmonary Mycobacterium avium complex lesion: A case report",
abstract = "Background: Biological agents inhibiting TNF-aα and other molecules involved in inflammatory cascade have been increasingly used to treat rheumatoid arthritis (RA). However, it remains controversial whether biological agents can be used safely in a patient with an underlying chronic infectious disease. Case presentation: A 63-year-old woman who had been treated with tocilizumab (TCZ), anti-interleukin-6 receptor antibody, for RA presented to our outpatient clinic due to hemoptysis. She was diagnosed with pulmonary Mycobacterium avium complex (MAC) infection, and high-resolution computed tomography (HRCT) showed a single cavitary lesion in the right upper lobe. After diagnosis of pulmonary MAC disease, TCZ was discontinued and combination chemotherapy with clarithromycin, rifampicin, ethambutol and amikacin was started for MAC pulmonary disease. Since the lesion was limited in the right upper lobe as a single cavity formation, she underwent right upper lobectomy. As her RA symptoms were deteriorated around the operation, TCZ was resumed. After resumption of TCZ, her RA symptoms improved and a recurrence of pulmonary MAC infection has not been observed for more than 1 year. Conclusion: This case suggested that TCZ could be safely reintroduced after the resection of a pulmonary MAC lesion. Although the use of biological agents is generally contraindicated in patients with pulmonary MAC disease, especially in those with a fibrocavitary lesion, a multimodality intervention for MAC including both medical and surgical approaches may enable introduction or resumption of biological agents.",
keywords = "Biological agents, Mycobacterium avium complex (MAC), Resection, Rheumatoid arthritis, Tocilizumab",
author = "Ho Namkoong and Sadatomo Tasaka and Mitsuhiro Akiyama and Kazuma Yagi and Makoto Ishii and Katsuya Suzuki and Mitsutomo Kohno and Naoki Hasegawa and Tsutomu Takeuchi and Tomoko Betsuyaku",
year = "2015",
month = "10",
day = "23",
doi = "10.1186/s12890-015-0130-z",
language = "English",
volume = "15",
journal = "BMC Pulmonary Medicine",
issn = "1471-2466",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Successful resumption of tocilizumab for rheumatoid arthritis after resection of a pulmonary Mycobacterium avium complex lesion

T2 - A case report

AU - Namkoong, Ho

AU - Tasaka, Sadatomo

AU - Akiyama, Mitsuhiro

AU - Yagi, Kazuma

AU - Ishii, Makoto

AU - Suzuki, Katsuya

AU - Kohno, Mitsutomo

AU - Hasegawa, Naoki

AU - Takeuchi, Tsutomu

AU - Betsuyaku, Tomoko

PY - 2015/10/23

Y1 - 2015/10/23

N2 - Background: Biological agents inhibiting TNF-aα and other molecules involved in inflammatory cascade have been increasingly used to treat rheumatoid arthritis (RA). However, it remains controversial whether biological agents can be used safely in a patient with an underlying chronic infectious disease. Case presentation: A 63-year-old woman who had been treated with tocilizumab (TCZ), anti-interleukin-6 receptor antibody, for RA presented to our outpatient clinic due to hemoptysis. She was diagnosed with pulmonary Mycobacterium avium complex (MAC) infection, and high-resolution computed tomography (HRCT) showed a single cavitary lesion in the right upper lobe. After diagnosis of pulmonary MAC disease, TCZ was discontinued and combination chemotherapy with clarithromycin, rifampicin, ethambutol and amikacin was started for MAC pulmonary disease. Since the lesion was limited in the right upper lobe as a single cavity formation, she underwent right upper lobectomy. As her RA symptoms were deteriorated around the operation, TCZ was resumed. After resumption of TCZ, her RA symptoms improved and a recurrence of pulmonary MAC infection has not been observed for more than 1 year. Conclusion: This case suggested that TCZ could be safely reintroduced after the resection of a pulmonary MAC lesion. Although the use of biological agents is generally contraindicated in patients with pulmonary MAC disease, especially in those with a fibrocavitary lesion, a multimodality intervention for MAC including both medical and surgical approaches may enable introduction or resumption of biological agents.

AB - Background: Biological agents inhibiting TNF-aα and other molecules involved in inflammatory cascade have been increasingly used to treat rheumatoid arthritis (RA). However, it remains controversial whether biological agents can be used safely in a patient with an underlying chronic infectious disease. Case presentation: A 63-year-old woman who had been treated with tocilizumab (TCZ), anti-interleukin-6 receptor antibody, for RA presented to our outpatient clinic due to hemoptysis. She was diagnosed with pulmonary Mycobacterium avium complex (MAC) infection, and high-resolution computed tomography (HRCT) showed a single cavitary lesion in the right upper lobe. After diagnosis of pulmonary MAC disease, TCZ was discontinued and combination chemotherapy with clarithromycin, rifampicin, ethambutol and amikacin was started for MAC pulmonary disease. Since the lesion was limited in the right upper lobe as a single cavity formation, she underwent right upper lobectomy. As her RA symptoms were deteriorated around the operation, TCZ was resumed. After resumption of TCZ, her RA symptoms improved and a recurrence of pulmonary MAC infection has not been observed for more than 1 year. Conclusion: This case suggested that TCZ could be safely reintroduced after the resection of a pulmonary MAC lesion. Although the use of biological agents is generally contraindicated in patients with pulmonary MAC disease, especially in those with a fibrocavitary lesion, a multimodality intervention for MAC including both medical and surgical approaches may enable introduction or resumption of biological agents.

KW - Biological agents

KW - Mycobacterium avium complex (MAC)

KW - Resection

KW - Rheumatoid arthritis

KW - Tocilizumab

UR - http://www.scopus.com/inward/record.url?scp=84944887084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944887084&partnerID=8YFLogxK

U2 - 10.1186/s12890-015-0130-z

DO - 10.1186/s12890-015-0130-z

M3 - Article

C2 - 26496968

AN - SCOPUS:84944887084

VL - 15

JO - BMC Pulmonary Medicine

JF - BMC Pulmonary Medicine

SN - 1471-2466

IS - 1

M1 - 126

ER -